We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

OmniAB Inc (OABI) USD0.0001 A

Sell:$4.13 Buy:$4.57 Change: $0.1 (2.20%)
Market closed |  Prices as at close on 17 May 2024 | Switch to live prices |
Change: $0.1 (2.20%)
Market closed |  Prices as at close on 17 May 2024 | Switch to live prices |
Change: $0.1 (2.20%)
Market closed |  Prices as at close on 17 May 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

OmniAb, Inc. offers a discovery platform that provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable the discovery of next-generation therapeutics. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. The Company’s OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach, and OmniTaur features structural attributes of cow antibodies for complex targets. The Company's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic target antigens.

Contact details

5980 Horton Street, Suite 600
United States
+1 (510) 2507800

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$531.84 million
Shares in issue:
117.62 million
Life Sciences Tools & Services
United States
US dollar

Key personnel

  • John Higgins
    Chairman of the Board
  • Matthew Foehr
    President, Chief Executive Officer, Director
  • Kurt Gustafson
    Chief Financial Officer, Executive Vice President - Finance
  • Charles Berkman
    Chief Legal Officer, Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.